Pataday, Zaditor, Lastacaft, and Stepwise Treatment
What these medications target
Most routine ocular allergy (seasonal or perennial allergic conjunctivitis) is driven by IgE-mediated mast cell activation. The hallmark symptom is itching, with chemosis and redness largely mediated by histamine and related inflammatory mediators. Treatment focuses on two practical targets:
- Antihistamine effect (H1 blockade): rapid itch relief and reduction in chemosis and redness.
- Mast cell stabilization: fewer flare-ups with continued exposure, with benefit building over days to weeks of consistent use.
Modern dual-action drops combine both mechanisms in a single formulation, which is why they have largely replaced older standalone antihistamines and standalone mast cell stabilizers for routine allergic conjunctivitis.
Dual-action drops: comparing Pataday, Zaditor, Lastacaft, and Bepreve
For uncomplicated allergic conjunctivitis, dual-action antihistamine/mast cell stabilizer drops are first-line. The most commonly used agents include:
- Olopatadine (Pataday, Patanol, Pazeo): the most widely prescribed allergy eye drop. Available OTC in multiple formulations: 0.1% (twice daily), 0.2% (once daily), and 0.7% (once daily, extra strength). Safe for ages 2 and up. Generally well tolerated with less stinging than ketotifen.
- Ketotifen (Zaditor, Alaway): available OTC, typically dosed twice daily. Approved for ages 3 and up. Effective and usually the least expensive option. May cause more stinging on instillation than olopatadine.
- Alcaftadine (Lastacaft): 0.25%, dosed once daily. Recently became available OTC. Blocks H1, H2, and H4 histamine receptors, which may provide broader anti-inflammatory effect. Approved for ages 2 and up.
- Bepotastine (Bepreve): 1.5%, dosed twice daily. Prescription only. Approved for ages 2 and up. Generally well tolerated but may cause mild taste disturbance.
In practice, selection is often driven by dosing convenience (once versus twice daily), cost and OTC availability, comfort on instillation, and contact lens compatibility. For contact lens wearers, once-daily dosing before lens insertion or after removal simplifies the regimen and avoids preservative accumulation on the lens.
When to add a steroid or escalate therapy
In more severe disease, dual-action drops may not be enough for the acute phase. Examples include marked papillary responses, significant contact lens-related giant papillary conjunctivitis (GPC), and vernal or atopic keratoconjunctivitis. In these settings, a short, closely monitored course of a lower-risk topical steroid, often a loteprednol formulation, can reduce inflammation so maintenance therapy becomes effective. Steroids should be tapered as signs improve and paired with IOP monitoring and appropriate follow-up. If dual-action therapy and a steroid pulse are still insufficient, consider referral for immunomodulatory therapy such as topical cyclosporine or tacrolimus in refractory atopic or vernal disease.
Contact lenses and preservative considerations
Many multi-dose allergy drops contain preservatives, commonly BAK, which can worsen surface irritation with frequent use and can bind to soft contact lenses. Standard counseling is to remove lenses, instill the drop, and wait 10 to 15 minutes before reinsertion unless the product is specifically labeled for in-lens use. Once-daily formulations such as Pataday 0.2% or 0.7% and Lastacaft are practical for lens wearers because dosing before insertion or after removal avoids the mid-day lens removal step. If a patient needs frequent dosing or has significant surface disease, consider temporarily reducing lens wear during flares.
Supportive measures and non-pharmacologic strategies
Drops work best alongside environmental and mechanical strategies. Cool compresses reduce periocular edema and provide immediate comfort. Preservative-free artificial tears dilute allergens on the surface and support the tear film, which is often disrupted during allergy flares. Counseling patients to avoid rubbing, which triggers further mast cell degranulation, and to shower or rinse the face after outdoor exposure can reduce allergen load significantly. If symptoms persist despite topical therapy, review contributing factors such as concurrent dry eye, blepharitis, or ongoing allergen exposure that could be addressed.